Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.60 |
| ▸ | MEN1 | O00255 | 5/20 | 0.60 |
| ▸ | CRHBP | P24387 | 2/20 | 0.54 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10167171 | 0.92 | KMT2A (0.59) | KMT2AMEN1MAPK1TSHRL3MBTL1 | |
| SCHEMBL3082913 | 0.80 | CPT1A (0.49) | KMT2AMEN1 | |
| SCHEMBL16948435 | 0.78 | KMT2A (0.66) | KMT2AMEN1TSHRATM | |
| SCHEMBL3096478 | 0.77 | POLB (0.47) | KMT2AMEN1CRHBPCRHR2TSHR | |
| SCHEMBL2800954 | 0.77 | KMT2A (0.61) | KMT2AMEN1CRHBPCRHR2MAPK1 | |
| SCHEMBL24286525 | 0.75 | KMT2A (0.67) | KMT2AMEN1TSHRATM | |
| SCHEMBL5829479 | 0.75 | KMT2A (0.78) | KMT2AMEN1TSHRATM | |
| SCHEMBL4869072 | 0.75 | CRHBP (0.62) | KMT2AMEN1CRHBPCRHR2MAPK1 | |
| SCHEMBL3622390 | 0.75 | KMT2A (0.63) | KMT2AMEN1CRHBPCRHR2MAPK1 | |
| SCHEMBL6087186 | 0.74 | L3MBTL1 (0.64) | KMT2AMEN1TSHRL3MBTL1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3140291-A2 | TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE | Lycera Corporation (US) | 2017-03-15 | — | — | EP | disclosed |